An advisory committee at the U.S. Food and Drug Administration has endorsed a novel experimental sleep therapy by CHI member Merck. According to Reuters, the experimental insomnia therapy, suvorexant, would be the first in a new line of sedatives designed to help people fall asleep and stay asleep, by targeting restless areas of the brain. [...]
and Innovation
CHI-California Healthcare Institute represents more than 275 leading biotechnology, diagnostics, medical device and pharmaceutical companies and public and private academic biomedical research organizations.